Global News

ThromboGenics publishes phase III data of ocriplasmin for VMT

Friday, August 17, 2012 03:11 PM

ThromboGenics, a Belgium-based biopharmaceutical company focused on ophthalmic medicines, has published data from two phase III clinical trials evaluating ocriplasmin for the treatment of Vitreomacular Adhesion (VMA) and macular holes in the New England Journal of Medicine.

More... »

Cinven to acquire Mercury Pharma

Friday, August 17, 2012 02:29 PM

Cinven, a European private equity firm, reached agreement to acquire Mercury Pharma, an international specialty pharmaceutical company, from owner HgCapital.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

IMS Health acquires TTC, strengthens pharma R&D services capabilities

Friday, August 17, 2012 11:27 AM

IMS Health, a global provider of information, services and technology for the healthcare industry, has acquired TTC, a Philadelphia-based benchmarking solutions and analytics company that helps life sciences organizations around the world plan for and negotiate the costs of clinical trials.

More... »

TG Therapeutics, Rhizen ink global agreement for TGR-1202

Friday, August 17, 2012 11:08 AM

TG Therapeutics, a clinical-stage biopharmaceutical company of New York, N.Y., and Rhizen Pharmaceuticals, a Switzerland-based biopharmaceutical company, have entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen's lead product candidate, TGR-1202, a novel PI3K delta inhibitor previously referred to as RP5264.

More... »

PatientsLikeMe, Merck collaborate on evaluating psoriasis impact

Friday, August 17, 2012 09:23 AM

PatientsLikeMe, a social networking health site, has entered into a collaboration with global pharmaceutical company Merck to evaluate the impact of psoriasis on patients and to inform a novel approach to improving outcomes.

More... »

INC Research promotes Macdonald to CEO, Ogle to continue as chairman

Friday, August 17, 2012 07:42 AM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO has, as part of a planned succession, promoted Chief Operating Officer Jamie Macdonald to president and Chief Executive Officer. Chairman and CEO James T. Ogle will continue to serve as chairman.

More... »

CROS NT appoints MacGarvey as vice president

Wednesday, August 15, 2012 02:01 PM

CROS NT, an international CRO specializing in clinical data services, has appointed Andrew MacGarvey as the vice president of U.K. and U.S. operations.

More... »

Arrowhead enters into antibody candidate evaluation agreement with Merck

Wednesday, August 15, 2012 11:27 AM

Arrowhead Research, a clinical stage targeted therapeutics company based in Pasadena, Calif., has entered into an agreement with global healthcare company Merck, through a subsidiary, to undertake an evaluation of a novel proprietary therapeutic monoclonal antibody candidate derived from Arrowhead’s human-derived peptide targeting and discovery program.

More... »

IMS Health expands suite of syndicated analytics with PharmaDeals acquisition

Wednesday, August 15, 2012 11:22 AM

IMS Health, a provider of information, services and technology for the healthcare industry, has acquired PharmaDeals, a provider of online information about business transactions, licensing, and mergers and acquisitions activity within the global pharmaceutical industry.

More... »